Flecainide News and Research

RSS

Flecainide is a drug used to treat abnormal heart rhythms. It may also relieve neuropathic pain, the burning, stabbing, or stinging pain that may arise from damage to nerves caused by some types of cancer or cancer treatment.

Discovery of molecular origins of a heart beat

Researchers have found that molecular origins of a heart beat. They have found the proteins that make up tiny sodium channels in the tissues of the heart that can help generate the heart beats. The results of the study titled, “Structure of the Cardiac Sodium Channel” was published yesterday 19th of December 2019 in the journal Cell.

22 Dec 2019

Atomic-level structure of cardiac sodium channel

Atomic-level studies of the architecture of tiny sodium channel proteins, critical to generating electrical signals that start off each beat of the heart, are imparting striking details about their function, malfunctions, disruption by many disease mutations, and response to medication.

20 Dec 2019

Anti-arrhythmic agents linked to increased risk of falls

Anti-arrhythmic drugs, particularly those used to treat atrial fibrillation, could increase the risk of fall-related injuries, a new study found.

29 Jul 2019

Research opens possibility of developing single-dose gene therapy for inherited arrhythmias

Researchers at Boston Children's Hospital report creating the first human tissue model of an inherited heart arrhythmia, replicating two patients' abnormal heart rhythms in a dish, and then suppressing the arrhythmia with gene therapy in a mouse model.

17 Jul 2019

ESC Guidelines recommend DNA analysis for post mortem assessment in young sudden death victims

ESC Guidelines published today recommend DNA analysis as a fundamental component of post mortem assessment in young sudden death victims. Identification of a genetic cause helps to quickly diagnose and protect relatives.

29 Aug 2015

ANI acquires approved ANDA for Flecainide Acetate tablets USP

ANI Pharmaceuticals, Inc. today announced that it has acquired the approved abbreviated new drug application ("ANDA") for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, previously marketed by Teva Pharmaceuticals.

5 Mar 2015

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.

8 May 2014

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.

23 Nov 2013

Flecainide, encainide drugs increase risk of sudden cardiac death

Scientists have discovered that a drug which increases the risk of sudden cardiac death interacts with mistranslated protein-coding genes present in heart muscle.

17 Sep 2013

Short-term antiarrhythmic drug treatment postcardioversion could be effective

Short-term antiarrhythmic drug treatment after cardioversion is less effective than long-term treatment, but prevents most recurrences of atrial fibrillation, a study in The Lancet shows.

21 Jun 2012

Antiarrhythmic short-term treatment useful for some patients

Atrial fibrillation (AF) is the most frequently sustained arrhythmia of the heart. It affects several million people in Europe. AF causes a loss of contraction in the atria and gives rise to heart failure. Moreover, it is associated with a high risk of stroke. One in five strokes is due to AF.

19 Jun 2012

Study supports catheter ablation as first-line treatment for paroxysmal atrial fibrillation

Patients with the heart rhythm disorder atrial fibrillation (AFib) who received first-line catheter ablation treatment had a longer arrhythmia-free interval than patients receiving antiarrhythmic drugs, the standard first-line treatment.

11 May 2012

UC Davis computer model can test effects of anti-arrhythmia medications

UC Davis researchers have developed an accurate computer model to test the effects of medications for arrhythmia, or abnormal heart rhythm, before they are used in patients.

2 Sep 2011

Strong link between leisure-time physical activity and AF among men

A Norwegian survey carried out between 1974 and 2003 showed that there was a graded independent increase in the risk of AF with increasing levels of physical activity in a population-based study among men with ostensibly no other heart disease. In women the data were inconclusive.

29 Aug 2011

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010